Adnkronos Rome, March 18 (Adnkronos Salute) – "Cardiovascular events remain the leading cause of death in Italy, Europe and the world, and this is what drives us not to stop. Our goal and our ambition is that no heart stops beating too soon. And to achieve this goal we continue to research and develop innovative therapeutic solutions for patients".
Chiara Gnocchi, country Comms & Advocacy head of Novartis Italy, said this this morning in Milan, during the meeting 'Not just LDL cholesterol: discovering Lipoprotein (a)', organized by the pharmaceutical company.
"Novartis has been present in the cardiovascular area for over 40 years – underlines Gnocchi – It is in fact an ongoing commitment that has seen us bring innovative therapeutic solutions in the field of heart failure and hypercholesterolemia. Our first commitment is to better understand science. This has allowed us to understand some prognostic and predictive factors on which to work, with therapeutic solutions that we are researching and developing, to reduce the risk of cardiovascular events".